Browsing Tag
CNS drugs
2 posts
Praxis Precision Medicines (NASDAQ: PRAX) surges 229% after breakthrough Phase 3 data in essential tremor
Praxis stock soared 229% on Phase 3 results for ulixacaltamide in essential tremor. Find out what this means for PRAX’s future and investor sentiment.
October 16, 2025
Can evenamide become the first real breakthrough for treatment-resistant schizophrenia?
Newron Pharmaceuticals reveals evenamide data at WCBP 2025, showcasing new hope for treatment-resistant schizophrenia through glutamate modulation.
September 5, 2025